Gonadorelin (Factrel / Lutrelef)
Synthetic GnRH hormone that starts the production of sex hormones; a prescription medicine in Europe, banned in sport.

DETAILED OVERVIEW
What is Gonadorelin (Factrel / Lutrelef)?
Gonadorelin (Factrel, Lutrelef) is a synthetic copy of GnRH, a hormone made in the brain, which via the pituitary gland starts the testicles' production of testosterone and sperm. In the United States it was approved for a diagnostic test and then withdrawn in 2008 for commercial rather than safety reasons; in Europe, Lutrelef is available to treat patients with hormone deficiency.
After steroid use, athletes try it to restart their own production, but the hormone is broken down very quickly, a single injection has limited effect, and only a pump can imitate the natural rhythm. When the signal is continuous, the receptors become insensitive and the production of sex hormones stops. Side effects include hypersensitivity (rarely anaphylaxis), reactions at the injection site and headache; self-administration with a pump also carries a risk of infection. It cannot be used with hormone-sensitive tumors. It is banned year-round in competitive sport. In humans it has mainly been studied in men with hormone deficiency, in smaller studies.
Mechanism
Stimulates the pituitary GnRH receptor; more testosterone
Half-life
~10-40 min (very short – pulsatility pattern is essential)
Onset
LH/FSH spike 15-60 min after SC
Legal status
FDA Factrel withdrawn 2008; EMA Lutrelef Ferring Rx (pulsatile-pump hypothalamic hypogonadism); WADA S2 Peptide Hormones banned
No anecdote collected yet.
Data console
Lab data
Wyeth-Ayerst Laboratories . Factrel (gonadorelin hydrochloride) for injection – FDA Label. FDA NDA 18123 (1982); US-discontinued 2008..
Ferring Pharmaceuticals . Lutrelef (gonadorelin acetate) – EMA Summary of Product Characteristics. EMA SPC, pulsatile-pump hypothalamic-hypogonadism indication..
Jiang H, Li BJ, Jin DC . Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study.. Transl Androl Urol.
Niu YH, Xu H, Chen YW . [Effect and safety of pulsatile GnRH therapy for male congenital hypogonadotropic hypogonadism].. Zhonghua Nan Ke Xue.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Hypersensitivity reactions, including rare anaphylaxis and antibody formation with repeated parenteral dosing (documented in FDA Factrel labeling: generalized urticaria, bronchospasm).
- Injection-site reactions: pain, redness, itching, swelling, rarely phlebitis; with pulsatile-pump protocols, ongoing cannula-site inflammation and infection risk.
- Headache, flushing, mild dizziness and nausea, often immediately post-injection, transient.
- Abdominal pain and discomfort, less commonly gastric complaints (reported in FDA Factrel labeling).
- With continuous (non-pulsatile) or prolonged dosing, paradoxical GnRH-receptor downregulation and desensitization: LH/FSH suppression and falling testicular testosterone (the chemical-castration mechanism of GnRH-agonist therapy).
- With pulsatile-pump protocols, overstimulation from increased gonadotropin drive: multiple follicular development and risk of ovarian hyperstimulation in women; transient secondary estradiol rise in men.
Contraindications · 6
- Known hypersensitivity to gonadorelin or GnRH analogues (prior anaphylactic or severe allergic reaction).
- Hormone-sensitive tumor or suspicion thereof (gonadotropin- or sex-hormone-dependent tumor) where LH/FSH stimulation is contraindicated.
- Pituitary adenoma, especially prolactinoma or gonadotroph tumor: GnRH stimulation carries a risk of pituitary apoplexy and abrupt hormone surge.
- Concurrent GnRH-agonist therapy (leuprolide/Lupron, goserelin/Zoladex): receptor-occupancy overlap and amplification of paradoxical receptor downregulation – not recommended.
- Pregnancy and breastfeeding: no established safety, axis stimulation not indicated; in fertility treatment only under endocrinologist supervision.
- Not indicated for self-treatment as AAS-PCT: pulsatile pump is impractical for self-injection, bolus protocol is evidence-poor, and lack of sterile technique creates infection risk.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Factrel (gonadorelin hydrochloride) for injection – FDA Label
Wyeth-Ayerst Laboratories
Lutrelef (gonadorelin acetate) – EMA Summary of Product Characteristics
Ferring Pharmaceuticals
Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study.
Jiang H, Li BJ, Jin DC
[Effect and safety of pulsatile GnRH therapy for male congenital hypogonadotropic hypogonadism].
Niu YH, Xu H, Chen YW
Telegram
Have a question about Gonadorelin (Factrel / Lutrelef)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.